Insights from 2023 ASH Annual Meeting
L

ASH 2023 Insights: "A Novel Beta Globin Frameshift Mutation Causing Autosomal Dominant Beta Thalassemia"

By Insights from 2023 ASH Annual Meeting FEATURING Lisa Bilston
By Insights from 2023 ASH Annual Meeting FEATURING Lisa Bilston
88 views
December 15, 2023
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
42:10
Insights from 2023 ASH Annual Meeting

Highlights in Red Cell and Platelet Disorders From ASH 2023

Feat. M. Blinder
13:57
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Pyruvate Kinase Activators - Targeting Red …

Feat. K. Kuo
10:22
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

State-of-the-Art in Managing Thalassemias

Feat. M. Cappellini
18:15
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Updates in Cellular Therapy for Sickle Cell Disease and Beta-Thalass…

Feat. S. Peslak
16:09
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Case-Based Discussion: Managing Non-Transfusion-Dependent Thalassemia

Feat. A. Taher
12:24
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

The Role of Luspatercept in Transfusion-Dependent Patients With Beta…

Feat. A. Tombak
08:41
ASH 2022 Conference Coverage

ASH 2022 Long-Term Outcomes of Patients With TDT Followed Up to 8 Ye…

Feat. M. Walters
09:49
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Bu-Cy or Treosulfan-Flu-Thiotepa-Based Myeloablative Conditioning fo…

Feat. N. Bayram
33:24
Zahra Pakbaz

Current Approach to Sickle Cell Anemia: COVID & SCD, Genotypes, …

31:43
Suhag Parikh

Updates on Curative Therapies for Sickle Cell Disease: Allogeneic HS…

10:26
James Taylor

Forms of SCD: Sickle Cell Anemia, Hb SC Disease, Beta/Alpha-Thalasse…

25:01
Indy Hematology Review

Review of Emerging Therapies and Top Trials in Hematologic Malignanc…

Feat. R. Birhiray
23:18
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Curative Options for Hemoglobinopathies: Is MSD the SoC in Thalassem…

Feat. S. Corbacioglu
28:21
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - Benign Hematolgy - Analysis of Top Trials

Feat. P. Harris
17:49
KU ASH 2019 Review: Current Updates in Hematologic Diseases

KU ASH 2019 Review on Benign Hematology: New FDA Approvals, 2nd-Line…

Feat. P. Harris
19:17
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Managing Late Complications in Beta Thalassemia: Thrombotic Disease,…

Feat. V. Huseynov
24:46
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on Non-Malignant Hematology: Mycophenolate for ITP, CTX0…

Feat. M. Thirman
13:05
KU ASH 2019 Review: Current Updates in Hematologic Diseases

KU ASH 2019 Review on Benign Hematology: Sutimlimab in CAD, Erythrof…

Feat. P. Harris
59:08
Vivien Sheehan

From Genomics to Biomarkers in Sickle Cell Disease: Can Genomics Reg…

30:41
Icahn School of Medicine at Mount Sinai

How to Approach Anemia

Feat. C. Cromwell